Browse News
Filter News
Found 269 articles
-
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
4/18/2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of AML.
-
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
4/10/2024
Moleculin Biotech, Inc. today announced positive preclinical data regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego, CA.
-
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
3/28/2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company) today announced Walter Klemp, President and Chief Executive Officer of Moleculin will present at the MedInvest Biotech & Pharma Investor Conference behind held in New York City, NY on Thursday, April 4, 2024 at 4:10 PM ET.
-
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
3/27/2024
Moleculin Biotech, Inc. announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Thursday, March 28, 2024 at 12:00 PM ET.
-
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
3/27/2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company) today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for U.S. Patent number 11,951,118 titled, "Preparation of Preliposomal Annamycin Lyophilizate" (the '118 patent') to be issued on April 9, 2024 to Moleculin and The University of Texas System Board of Regents.
-
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
3/25/2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, provided a preliminary update on recent clinical activity and expected near term milestones for its lead program MB-106 for the treatment of Acute Myeloid Leukemia (AML) following its Fiscal Year 2023 filing with the Securities and Exchange Commission.
-
Moleculin Reports Full Year 2023 Financial Results
3/22/2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2023.
-
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
3/20/2024
Moleculin Biotech, Inc. today announced that it will report its financial results for the year ended December 31, 2023, on Friday afternoon, March 22, 2024.
-
Moleculin Announces Reverse Stock Split - March 19, 2024
3/19/2024
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, announced a 1-for-15 reverse stock split of its common stock.
-
Moleculin to Present at the 36th Annual ROTH Conference
3/12/2024
Moleculin Biotech, Inc. today announced Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024 at 9:00 AM PT.
-
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
1/24/2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced 2023 year-end Annamycin clinical trials preliminary data and 2024 expectations for multiple data readouts and a transition to pivotal Phase 2B/3 clinical studies.
-
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
12/21/2023
Moleculin Biotech, Inc. announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor and certain of the Company's executive officers and directors to purchase 7,044,836 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
-
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
12/11/2023
Moleculin Biotech, Inc. today announced the presentation of preliminary efficacy findings from the Company's ongoing European Phase 1B/2 clinical trial evaluating Annamycin for the treatment of acute myeloid leukemia or AML (MB-106).
-
Moleculin Reports Third Quarter 2023 Financial Results
11/13/2023
Moleculin Biotech, Inc. reported its financial results for the quarter ended September 30, 2023.
-
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
11/13/2023
Moleculin Biotech, Inc. today provided a preliminary update on recent clinical activity and expected near term milestones across its clinical development pipeline in its quarterly filing with the Securities and Exchange Commission.
-
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
11/7/2023
Moleculin Biotech, Inc. , today announced that it will report its financial results for the third quarter ended September 30, 2023 , on Monday November 13, 2023. Moleculin management will host a conference call and live webcast to discuss the operational and financial results at 8:30 AM ET that same day.
-
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
11/6/2023
Moleculin Biotech, Inc announced the presentation of preliminary efficacy findings from the Phase 2 portion of the Company's ongoing U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
-
Moleculin to Participate in the Virtual Investor Ask the CEO Conference
10/11/2023
Moleculin Biotech, Inc. today announced that Walter Klemp, President and Chief Executive Officer and Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin, will participate at the Virtual Investor Ask the CEO Conference on Tuesday, October 25, 2023 at 12:00 PM ET.
-
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
10/2/2023
Moleculin Biotech, Inc. today announced the initial subjects have been treated in the Phase 2 portion of the Company's Phase 1B/2 trial evaluating Annamycin in combination with Cytarabine (Ara-C) for the treatment of subjects with AML (MB-106).
-
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)
9/21/2023
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat cancers and viruses, today announced the completion of enrollment in the Phase 2 portion of the Company's U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).